Business
Decision Diagnostics' Panacea Genprecis! Product Moves into Pre-Production, First Round Clinical Trials to Begin in the Next 30 Days
Decision Diagnostics' Panacea Genprecis! Product Moves into Pre-Production, First Round Clinical Trials to Begin in the Next 30 Days.
About this update from Decision Diagnostics Corp
[{"type":"text","content":"Initial Testing Proves DECN's GenPrecis! System is Performing Above and Beyond Published Standards, Looking Toward Becoming an Industry Legacy in its Own RightLOS ANGELES, CA / ACCESSWIRE / March 21, 2018 / Decision Diagnostics Corp. (OTC PINK: DECN) is a manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate! (\"Sunshine\") diabetes test strip, the new internationally launched GenSure! (\"Feather\") diabetes test strip, and the GenChoice! \"Ladybug\" diabetes test strip now in clinical trials.Today, we are excited to discuss the progress and the successes we have had with our panacea system, GenPrecis!. We are pleased to report our progress is ahead of schedule and set for International launch in late spring 2018, a more precise date shall be announced in coming weeks.Keith Berman, CEO of Decision Diagnostics, commented, \"In the past 90 days we have finished the development of the GenPrecis! system proving to ourselves and our partners that we have created a panacea product that promises to provide the most accurate glucose results of all commercially available glucose monitoring systems. GenPrecis!, in fact, is now performing as well as many hospital-based bedside chemistry analyzers.\"GenPrecis! is designed to exceed published performance standards for at-home glucose devices by as much as 50%, while operating in a \"portable package\" small enough to fit comfortably in the hand of an 11 or 12-year-old, while providing glucose results to diabetics for less than $.25 per strip.The need for a product such as GenPrecis! has become even more critical and pronounced with continuous monitoring products entering the marketplace. GenPrecis! fills a demand vacuum by operating with greater precision, but also by providing innovative wireless data exchange, all in a small hand-held meter. In addition to our \"25 cent\" precise solution, we anticipate that GenPrecis! Precise meters will be provided to the diabetic free of charge.Mr. Berman continued, \"If we benchmark a static growth rate of at-home glucose solutions in the worldwide markets, DECN forecasts a 6% market share for GenPrecis!, by 2022. With the average usage of three test strips per day ($.75), we believe that GenPrecis!, could generate revenues in...